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Abstract
Background: Patents are one of the most important forms of intellectual property. They grant a time-limited exclusivity on
the use of an invention allowing the recuperation of research costs. The use of patents is fiercely debated for medical
innovation and especially controversial for publicly funded research, where the patent holder is an institution accountable
to public interest. Despite this controversy, for the situation in Germany almost no empirical information exists. The purpose
of this study is to examine the amount, types and trends of patent applications for health products submitted by German
public research organisations.
Methods/Principal Findings: We conducted a systematic search for patent documents using the publicly accessible
database search interface of the German Patent and Trademark Office. We defined keywords and search criteria and
developed search patterns for the database request. We retrieved documents with application date between 1988 and 2006
and processed the collected data stepwise to compile the most relevant documents in patent families for further analysis.
We developed a rationale and present individual steps of a systematic method to request and process patent data from a
publicly accessible database. We retrieved and processed 10194 patent documents. Out of these, we identified 1772
relevant patent families, applied for by 193 different universities and non-university public research organisations. 827 (47%)
of these patent families contained granted patents. The number of patent applications submitted by universities and
university-affiliated institutions more than tripled since the introduction of legal reforms in 2002, constituting almost half of
all patent applications and accounting for most of the post-reform increase. Patenting of most non-university public
research organisations remained stable.
Conclusions: We search, process and analyse patent applications from publicly accessible databases. Internationally
mounting evidence questions the viability of policies to increase commercial exploitation of publicly funded research
results. To evaluate the outcome of research policies a transparent evidence base for public debate is needed in Germany.
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Introduction
Intellectual Property (IP) protection and its effects on health
have been controversially discussed for years. On the one hand, IP
protection is considered essential as an incentive for innovation
and investment in research and development (R&D) [1,2,3].
Researching entities can expect to recoup the extensive costs of
successful research since they are granted exclusive protection on
production and marketing of a resulting commercial product. On
the other hand IP protection is considered as conflicting with
human rights [4,5], especially where prices for pharmaceutical
products are regarded as inhibiting access to health products [6].
Exclusivity of products, brought about through patenting or
exclusive licencing, can affect pharmaceutical prices and afford-
ability, especially in developing countries [7].
An important part of knowledge generation is financed by
public funding [8,9]. In particular, the initial stages of R&D are
performed by universities and other publicly funded institutions
[10]. Beginning in the US, there has been a consistent trend
of increasing IP protection of publicly financed research
[11,12,13,14]. In the context of publicly funded research, IP
protection is facing an even more complicated set of supporting
and challenging arguments in addition to those mentioned
above.
Arguments supporting IP protection of publicly funded research
include:
1. Publicly funded research organisations have limited budgets –
the licensing of IP rights is believed to bring additional funding
for R&D [15].
2. Publicly funded basic research that can be commercialized
could spur science-based economic growth [12,16].
3. Implementing IP management might be necessary for bridging
the technology transfer gap. Private investors for advanced
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has already been obtained [17].
Arguments opposing IP protection of publicly funded research
include:
1. IP protection could hamper the possibilities of further research,
cutting off researchers from using the results of others [18,19].
2. Many public research institutions in the US spend more on IP
protection than they earn from it. In these cases, IP protection
is not financially beneficial [20].
3. IP protection can lead to increased prices for products to
patients and public health systems [21]
4. From a political and moral standpoint, the results of publicly
funded research should always be public and not used for
private benefit [18].
In Germany during the late 1980s and 1990s, global free-
market forces led the German government to push for greater
commercialisation of research. Firstly, society had begun to expect
a return on investment from public research and, secondly, the
realisation of the shift from an industrial to knowledge based
society put emphasis on the exploitation of knowledge [16]. In
2001, the German Federal Ministry of Education and Research
initiated a research policy shift to push for utilisation (Verwertung-
soffensive) of research results [22]. Within this policy shift the
German framework for IP on university research was changed
with the 2002 reform of the Law on Employees’ Inventions (Gesetz
u ¨ber Arbeitnehmererfindungen) [23].
These adjustments were modelled on the results of the
fundamental changes in public patenting brought about by the
Bayh-Dole Act in the US in 1980 [24]. In Germany before 2002,
university professors had the freedom to decide whether or not
they wanted to patent inventions resulting from their work. They
were invited to use the services of university technology transfer
offices (TTOs). The 2002 legal reform altered the situation: All
professional inventions became attributed to the university. The
university is entitled to claim the invention from the inventor and
to apply for a patent. Only if the university decides not to exert this
right, are professors or researchers allowed to file a patent
application by themselves. Publicly funded research organisations
in Germany are still not, however, required by law to disclose any
patents on inventions arising from their research.
Although the issue is controversially debated internationally,
little empirical data is available concerning IP on health products
from publicly funded research. Some data on the situation in the
US have been analysed [12,25,26]. In Germany, until now only a
general analysis of university patents has been performed [27].
Data on some patent applications from German medical faculties
is available online [28], but the detailed methodology used to
collect this data has not been published. A long-term evaluation of
patenting of health products by universities and non-university
public research organisations (PRO) in Germany has not been
conducted. To enable an informed debate, the objective of this
study is to analyse how patents on health products, applied for by
universities and non-university PROs in Germany, can be
identified and how many patents these institutions have applied
for.
Methods
We decided to take on a patent research approach. We
extracted patent documents concerning health products developed
by German universities and non-university PROs from the
publicly accessible database of the European Patent Office
(EPO). We used the DEPATISnet advanced search interface
provided by the German Patent and Trademark Office (DPMA,
Deutsches Patent- und Markenamt) [29].
We defined our search criteria as:
1. Patent documents returned by a search request on October 10,
2008, using the DPMA online search interface
2. Documents referring to patent applications submitted between
January 1, 1988 and December 31, 2006
3. Applications originating from an applicant in Germany
4. Applicants being either a
a. university or university-affiliated institution or a
b. non-university PRO, i.e. a member of Helmholtz-
Gemeinschaft, Max-Planck-Gesellschaft, Leibniz-Ge-
meinschaft or Fraunhofer-Gesellschaft or a
c. ‘‘Patentverwertungsagentur’’ (equivalent to a TTO)
of universities or non-university PROs, i.e. a member
organisation of TechnologieAllianz [30] or a
d. federal institution of the German state
5. Documents relating to a product classified in the sector of
‘‘medical science’’ according to the International Patent
Classification (IPC) main class [31].
The four main non-university PROs were considered. The
Helmholtz Gemeinschaft (Helmholtz Association) is a community
of scientific-technical and biological-medical research centres
commissioned to pursue long-term research goals on behalf of
the state and society [32]. The Max-Planck-Gesellschaft (Max
Planck Society) conducts basic research in life sciences in the
interest of the general public. The Society takes up research areas
to complement work done at universities or that universities are
not in a position to accommodate or deal with adequately [33].
The Leibniz Gemeinschaft (Leibniz Association) research institu-
tions address scientific issues of importance to society as a whole.
They conduct natural science research cooperating with univer-
sities and complementing university research while their academic
staff also hold joint academic appointments [34]. The Fraunhofer-
Gesellschaft is Europe’s largest application-oriented research
organization, promoting and undertaking applied research for
direct utility to private and public enterprise and of wide benefit to
society as a whole. The Society aims to promote the economic
development with particular regard for social welfare and
environmental compatibility [35].
We designed our search request to increase sensitivity despite
the high number of spelling (and mis-spelling) variants in applicant
names.
The IPC classifies patents by their main purpose. We searched
for several subclasses of IPC class A61 (‘‘Medical or veterinary
science; Hygiene’’), excluding all subclasses with other purposes
than human medicine. Patent applications only classified in IPC
section C (‘‘Chemistry; Metallurgy’’) were not searched for, as
within this section it is not possible to distinguish between
inventions for medical purposes and others inventions. Discussion
of ‘patents’ hereafter refers only to patents in the above IPC
classification. For a detailed description on the search request
used, refer to Annex S1.
Inventions originating from research at universities are not
included if patents were solely filed by industry research partners.
We subsequently processed the resulting datasets through a
series of steps. In further steps, we added extra columns for data
calculated from pre-existing columns. (Explanations of the
Patenting of Public Research
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datasets after each step are presented in the Results section.)
Initial data processing
Step Task
1) We assembled data gathered by database requests to the
DPMA interface in a Microsoft Access 2003 database.
2) We deleted duplicate entries from the database.
3) We deleted documents on utility models.
Applicant data processing
Step Task
4) We extracted the content of the ‘‘applicant’’ column into a
separate applicant table.
5) From this applicant table, we removed applicant entries
where no applicant met our inclusion criteria.
6) For the remaining entries in the applicant table, we
developed the table into a substitution list: We associated
each original applicant entry with up to five single applicants
in a consistent notation.
7) We associated each applicant with one of the following
groups:








i. hide from table (applicants not covered by inclusion
criteria)
8) We associated the main table from step 3 (see above) with the
applicant substitution table from step 4–7.
Patent family processing
Many patent applications are first filed in the applicant’s home
country and only later submitted in other countries, at the
European Patent Office (EPO) or at the World Intellectual
Property Organization (WIPO). This results in so-called ‘‘patent
families’’, constituted by several patent documents – often from
different countries – all referring to a single first patent application
based on the same research result (invention). As we relied on the
DPMA search engine’s patent family search, we used the DPMA
definition of a patent family as ‘‘a group of patent applications and
grants […] which are all directly or indirectly related to each other
by way of a common priority’’ [36].
We considered only the most relevant document from each
patent family and excluded additional documents within the same
patent family. Deciding on the most relevant document in a patent
family, however, is not a straightforward task. For our purposes,
our first decision criterion was the scope of a patent document: If a
patent had been submitted to WIPO, this document was
considered the most relevant. Second highest relevance was given
to documents from applications to EPO. Only if there were no
documents from applications to WIPO or EPO, was the first
application in a single country considered as the most relevant
document. If there were several documents with equal scope in a
patent family, we considered the document with the earliest
application date to be the most relevant.
Step Task
9) Using a patent family request (for details see Annex S2), we
evaluated the patent family for each document: If one patent
application inside a patent family had been granted, we
tagged all documents in this family as granted. In the
following steps, we used only the most relevant document in
each family. We hid all other documents from the table.
Data preparation for statistical evaluation
Step Task
10) We created a new table containing one entry per document
per applicant using a UNION-request (for details see Annex
S3). In this table a document with for example two applicants
appears twice.
11) We created a new table only containing documents where at
least one applicant is a university or university-affiliated
institution using a selective request based on the data from
step 9 (for details see Annex S3).
12) For the data from step 11 (see above), we created a new table
containing one entry per document per applicant (similar to
step 10 above).
Further Data Processing
We imported the tables from steps 9 to 12 (see above) into
Microsoft Excel 2003 worksheets. In each worksheet we added one
column ‘‘application year’’, based on the already available
application date information. Additionally, we added one column
‘‘country code’’, based on the country information available from
the document identification number.
We added another column, grouping country codes into one of
the following groups:
a. International patent application – according to Patent
Cooperation Treaty (PCT)
b. European patent application
c. Patent application in Germany
d. Patent application in other countries
We added a column ‘‘weighting’’. Its content was calculated as
one divided by the number of applicants.
Only patent application documents submitted between 1
January 1988 and 31 December 2006 were included, given that
we conducted our first database search on 1 July 2008 and 18
months before this search date no public disclosure of application
submission is required.
We processed all retrieved patent applications that matched our
search criteria. Because of possible bias due to the different
patenting policy in eastern Germany (GDR) until 1990, we also
performed subgroup analysis for the time period from 1997 to
2006 to analyse accessible applications of the past 10 years.
Given the high number of documents to be considered, an
exhaustive case-by-case evaluation to identify patent families was
not feasible. We therefore used a step-wise approach: If a patent
family contained an international (WIPO) application under the
PCT, we considered this document as the most relevant. An
international application theoretically enables the applicant to
Patenting of Public Research
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[3]. When there was no international application, we looked for an
EPO application, valid for 35 member states as of January 2009
[37]. If no multi-country (WIPO or EPO) application existed, we
considered the first application in a single country as the most
relevant. As we investigated R&D results from Germany only, this
was also the country of the first application in almost all cases.
Results
Results of Data Processing
Figure 1 presents a graphical depiction of the processing (by
each numbered step) and results of data extraction.
The initial dataset retrieved using the DPMA search engine
resulted in a total of 10194 entries (step 1). After deleting duplicate
entries and documents referring to utility modes, 8709 documents
remained (step 2 to step 3).
We then processed the applicant strings, removed documents
where no applicant met our inclusion criteria and adjusted for
variations in applicant spelling (step 4 to step 6). This resulted in
367 different applicants, which were stratified into nine groups
(step 7). Of all 367 applicants, 193 matched our inclusion criteria.
All others were excluded from further evaluation.
We associated the document datasets from step 3 with the applicant
substitution table from step 7. We excluded 4530 patent documents
(52.0%) for which applicants did not meet the inclusion criteria. The
resulting database contained 4179 patent documents (step 8).
After evaluation of patent families (for details see Annex S2),
1772 documents were considered most relevant for their respective
patent family. Out of these 1772 patent family documents, we
marked 827 (46.7%) documents as granted in at least one country
(step 9). The remaining 945 (53.3%) applications were either not
granted or were still being processed.
When documents were listed per applicant, out of the 1772
documents mentioned above, 2092 applicants were considered.
This resulted in an average of 1.18 applicants per document (step
10).
Considering only documents where at least one applicant was a
university or university-affiliated institution, 859 documents
remained (step 11). Of these, 334 (38.9%) had granted patents
in their patent family. These documents had 914 applicants, an
average of 1.06 applicants per document (step 12).
Results of Dataset Analysis
The distribution of patent applications on health products
submitted by various German PROs in 10 years is shown in
Figure 2. Universities and university-affiliated institutions submit-
ted almost half (48%) of all PRO patent applications. In terms of
the main non-university PROs, the institutes of Helmholtz-
Gemeinschaft submitted one fifth of all patent applications on
health products – more than double the number of applications
from each of the other three non-university PROs individually
(22% compared with 4–10%).
Technology transfer offices were hardly ever mentioned as an
applicant. In some cases, the applicant was a federal agency of the
Federal Republic of Germany.
The top German universities and university-affiliated institu-
tions in terms of the number of patent applications submitted
during the period 1997 to 2006 is shown in Figure 3. In some cases
university-affiliated institutions appear independently from the
university. For example, Charite ´ – Universita ¨tsmedizin Berlin
appears independently of Humboldt University, and the Univer-
sity Hospital Freiburg appears separately from University
Freiburg.
Over this ten-year period, no more than 70 patent applications
on health products were submitted by any one university or
university-affiliated institution. On average, 22 patent applications
were submitted per university or university-affiliated institution
during this period, and only the top eight were above this average
– accounting for 60% of all applications.
Figure 4 shows the patent applications for non-university PROs
over the same ten-year period.
The number of patent applications by all PRO groups per year
for the period 1988 to 2006 is shown in Figure 5. The German IP
legal reforms were introduced in 2002. The number of patent
applications per year submitted by university and university-
affiliated institutions has more than tripled since then, from 44 in
2002 to 143 in 2006. The number of applications by the other
non-university PROs, however, has remained relatively stable
before and since 2002.
The number of patent applications submitted by universities
and Helmholtz-Gemeinschaft also doubled between the mid-1990s
and the early 21
st century – before the reforms. Since 2000,
however, the number of patent applications submitted by the
Helmholtz-Gemeinschaft has decreased by more than half.
German reunification in 1990 changed patenting policy. A
significant decrease in patent applications by university and
associated institutions from 1989 to the early 1990s can be noted.
Finally, medical-science research by university and university-
affiliated institutions still amounts to less than 150 PCT
applications for health products in 2006 - and much less before
that.
Figure 6 shows the distribution of the highest level patent
applications submitted to each type of patent office. More than
40% of all patent applications were only submitted to the German
Patent and Trademark Office (DPMA) and approximately 40%
were submitted to WIPO for the PCT process in addition to the
first application at some national patent office. Less than 10% of
all patents were applied for at the European level (EPO), but not
submitted to WIPO for the PCT process, and even less were only
submitted to a foreign patent office, for example the US Patent
and Trademark Office (USPTO).
Over the years, applications to only DPMA and EPO have
relatively decreased, while the percentage of PCT applications has
increased relatively and absolutely.
In the final stage of the analysis, we examined the number of
patent applications and patent grants per year by German PROs
for the period 1988 to 2006 (Figure 7). The total number of patent
applications submitted annually increased quite steadily during
this period: from around 35 applications per year in the early
1990s to 218 applications in 2006. The proportion of granted
patents among these applications is on average 70% until 2000,
decreasing since then.
The data provided by our source does not allow to distinguish
between denied and pending applications. Therefore the closer we
get to the present day, the higher the proportion of patent
applications from recent years which are still pending.
Discussion
German government policy on patenting aims to create more
opportunities to exploit research results commercially, in partic-
ular those from publicly funded research. The debate on publicly
funded research and its associated responsibility towards the public
is gaining momentum. The debate originated around commercia-
lisation of university inventions and then gathered increasing
attention in relation to cases of patents and licences for medicines,
with specific focus on access to them in the developing world
Patenting of Public Research
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Figure 1. Stepwise Presentation of Results from Data Extraction and Processing.
doi:10.1371/journal.pone.0014059.g001
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in high-income countries as well. Health systems financing, its
relevant associated governmental policies, and the rising costs for
pharmaceutical products are coming increasingly into the focus of
public attention [40,41].
The purpose of this research is to examine the patterns of
patenting on health products, applied for by German university and
non-universityPROs.Thisresearch willenable and contributetoan
informed debate on patenting by PROs in Germany.
In Germany, the patent applicant is not required by law to
disclose information on patents resulting from publicly funded
research. The DPMA is legally required after 18 months to publish
details for all patents applied for. Therefore, the DPMA database
is the only publicly accessible data source that comprehensively
details all patents applied for in Germany.
Since we could not identify any established methods to answer
our questions, we developed a new method to search for and
process data from patent applications. We chose to acquire our
patent data through the DPMA database to allow for systematic
analysis and to avoid various biases associated with alternative
methods, such as surveying research institutions on patenting.
We begin with a discussion of this method before moving on to
discussion of our research findings.
Discussion of Method
We developed and present a new method to extract and process
data on patent applications for medical science inventions by
universities and PROs in Germany using a publicly accessible
database. Using our method we were able to identify and retrieve
patent documents selectively for a defined group of applicants and
covering a defined field of inventions. We searched the DPMA
database for patent documents from universities and non-
university PROs in the field of health products. We extracted
necessary data from identified documents and processed them for
further statistical analysis of applicant activity, range of patent
protection, IPC main class or longitudinal development.
A search request sent to the DPMA advanced search interface
can combine several search criteria, however searches soon
become highly complex. Careful attention must be paid to
drafting the search request in a way that corrects for the high
number of variations in spelling and typographic errors in the
database. For example, amongst applicants we found eleven
different versions of spelling for ‘‘Charite ´ Universita ¨tsmedizin
Berlin’’, the medical faculty of the Berlin universities. Labour-
intensive processing is necessary to exclude false-positives (52% of
all documents), harmonize all spellings and to prepare data for
further analysis.
The classification of patent application documents is also not
entirely consistent across patent documents from within one patent
family. As we only included documents classified by patent offices
as health products according to IPC, we may have missed other
relevant inventions. For example, inventions classified in chemistry
or cosmetics may later be used for medical purposes. Publicly
funded research in a medical research laboratory may also result
Figure 2. Number and percentage of medical-science patent applications (N=1220) by German public research organisations,
1997–2006.
doi:10.1371/journal.pone.0014059.g002
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category, for example, information technology.
Documents were flagged as ‘‘granted’’ if at least one document in
their patent family was a document granting a patent. We used this
simplification to allow for quantitative analysis. WIPO does not
grant patents; it only facilitates the application process. Therefore,
WIPO applications (identified as the most relevant document in the
patentfamily)wereflaggedasgrantedifthepatentfamilycontained,
for example, a granted patent from EPO. In many cases, however,
other countries simply follow the grant decision of EPO as they
cannot afford the same level of extensive search and patentability
checking.Thetime lag betweenapplication andgranting ofa patent
also requires such simplification, as applications granted by one
patent office may still be pending by another.
The complexity and number of issues we encountered in
developing this method highlights how complex the patent
database system is to use. The resulting datasets require several
steps of refinement before being suitable for statistical analysis.
Nevertheless, we believe our stepwise method can be replicated by
others for different IPC classes in Germany. In term of
generalisability, we believe our stepwise approach could be
applied to similar databases available in other countries.
Increased patenting by universities and university-
affiliated institutions
Since the 1990s there has been a clear and substantial increase
in the number of patent applications submitted each year by
German PROs. German university and university-affiliated
Figure 3. Number of medical-science patent applications submitted by German universities and university-affiliated institutions,
1997–2006.
doi:10.1371/journal.pone.0014059.g003
Figure 4. Number of medical-science patent applications submitted by main German non-university public research organisations,
1997–2006.
doi:10.1371/journal.pone.0014059.g004
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doi:10.1371/journal.pone.0014059.g005
Figure 6. Number of patent applications by German public research organisations submitted at different patent offices, 1988–
2006.
doi:10.1371/journal.pone.0014059.g006
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applications and are responsible for most of the overall increase.
This has largely taken place since the 2002 legislative reforms.
Other non-university PROs, however, were not found to be
submitting patent applications at a higher rate, and there are even
indications of a trend of decreased patent submissions.
We consider that a significantpart oftheincrease maybe because
patent applications previously submitted by individual researchers
are now registered under the university name. This would be in
accordance with the 2002 legal reforms in Germany. Other
researchers have found clear empirical evidence from European
countries, including Germany, that the number of university-
invented patents is much higher than the number of patents owned
by universities [42]. This might be related to the tendency in the
1980s and 1990s for patent ownership to be assigned to the industry
partner that financed the research project, with researchers and
professors only included in the list of inventors.
Very few assessments have been conducted analysing the
number of patents applied for by individual researchers or
research organisations in Germany prior to the 2002 legislation
changes [43,44]. It therefore remains questionable whether
research at university and university-affiliated institutions has
resulted in more patents and commercially developed products. In
fact, it appears to the authors nearly impossible methodologically
to collect such figures from existing patent databases, since this
would require searching for individual researchers. Furthermore,
the databases do not indicate if patented inventions are a result of
publicly funded research.
Patent applications by non-university PROs other than
Helmholtz-Gemeinschaft have remained relatively stable over
time and do not show the post-reform increases demonstrated by
universities. The number of patent applications submitted by
universities and Helmholtz-Gemeinschaft doubled between the
mid-1990s and early 2000s, before the legislation reforms were
introduced [16,22]. This points to the importance of factors other
than national legal change.
So et al warns against interpreting data that patents have
increased as evidence of increased commercialisation or actual
technology transfer of public research [14]. Furthermore, they
caution against attributing such increases to changes in national IP
policies. There is some evidence that the international rise in
patenting by universities has been driven by increases in
technological opportunities in the biomedical and biotechnology
sectors, more so than by IP policy changes [43,45]. Alternatively,
researchers, TTOs and universities may feel a great pressure (real
or perceived) to submit more patent applications, as patenting
becomes increasingly expected and a common evaluative indicator
for individual research output performance.
Our finding of an increase in patent applications could be an
indication that the legal reforms have been successfully applied
with the instigation of the TTOs (Patentverwertungsagenturen). A
study by Saragossi and Van Pottelsberghe found that the increase
in patents in Belgian universities was also related to more effective
TTOs [46], although a simple increase in TTO quantity could
also be responsible for the increase in patenting. In line with this,
Baldini found that in Italy a lack of university support mechanisms
– including TTOs and a lack of funds to cover patenting costs –
were associated with lower patenting, while availability of
administrative and TTO structures was associated with increased
patenting [47,48].
The number of patent applications by university institutions
decreased significantly from 1989 to the early 1990s. The decrease
Figure 7. Patent applications and granted patents by year of application, 1988–2006.
doi:10.1371/journal.pone.0014059.g007
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applications. We believe this reflects different patent legislation
and patenting policies at universities in the former German
Democratic Republic.
Time-lag between patent submissions and outcomes
The increase in patent applications during the 1990s was
accompanied by an increase in the number of applications
granted. From 2001, however, patent applications continued to
increase while the number and proportion of granted patents
found inthedatabasedecreased. The data providedby the patent
database does not allow for distinguishing between rejected and
still pending applications. According to German patent law
(patG, 131 [2]2.), while patent offices are required to publish
applications after 18 months, issuing a decision on whether or not
the patent will be granted takes on average around 2–2.5 years
[49].
This could explain why only 46.7% of the documents in our list
are marked as granted, whereas annual data on applications with
completed examination suggests a grant rate in Germany of about
53% [50]. We can therefore assume that about 6% of total
applications are still pending, mainly those filed in the most recent
years.
Heterogeneity of universities and university-affiliated
institutions
We calculated the top 25 German universities and university-
affiliated institutions in terms of the number of patent applications
submitted between 1997 and 2006. The number of applications
submitted by each entity was relatively low – on average 22
applications per university and university-affiliated institute, with
the top eight universities accounting for 60% of all applications.
Baldini showed that the availability of a medical school to the
university was related to higher patenting activity at Italian
universities [47,48]. In our analysis, amongst the top 25 patent
submitting universities in Germany, only the University of
Ilmenau had no medical faculty, although they have an Institute
for Biomedical Engineering and Informatics.
We could not conclusively determine a specific communality
between the universities with the highest patenting activity, such as
university size or size of the city where the university is located.
Thus, for the most part our findings are in line with the evidence
that other factors play a significant role in the patenting activity of
individual universities. Such factors include the financial resources
and level of R&D funding, the economy and industrial strength
and structure in the university’s surroundings, royalty distribution
practices and the university’s commitment to exploit inventions
[45,47]. Thus, it cannot simply be assumed that universities are
the most productive research institutions or that others, such as
Helmholtz-Gemeinschaft, are more efficient than its other non-
university PRO counterparts.
The relatively small number of patent applications submitted is
striking. All medical-science research from universities and
university-affiliated institutions still amounted to less than 150
WIPO patents applications in 2006 and much less before that. A
study by Malik revealed that US and UK universities patent much
more than Germany or France [51]. For the period 1994 to 2005,
the US submitted 18.9 biotechnology patents per million
inhabitants, while Germany submitted only 0.11 patents per
million inhabitants. Lehrer discusses university entrepreneurialism,
postulating that it depends on ‘structured interface between the
invisible hand of market forces and the visible hand of public R&D
funding’ [52].
Policies and responsibilities for patenting of publicly
funded research
The policy reforms on patenting by universities and non-
university PROs in Germany were designed to increase the
technology transfer and commercialisation of publicly funded
research. Increases in patent submissions or approved patents do
not necessarily indicate increased or improved commercialisation.
Patent applications are not of equal value – the commercial
potential of patents differs greatly and may change over time. Also,
the commercial viability or successful application of a patented
invention is not always guaranteed. Econometric evidence from
the US indicates that revenue from increased commercialisation of
public research does not necessarily outweigh costs associated with
patent management [14]. If the same pattern applies for Germany,
increased patenting may hamper economic and knowledge
development.
The evidence from the US and other countries draws into
question the underlying objective of the German policy changes.
From patenting figures presented here, it is not possible to look
into the commercial success or sustainability of the increased
patenting. To our knowledge, in Germany figures on commercial
returns are neither collected systematically at an aggregated
federal level or made publicly available at patent or institutional
level. The justification of these policies and their evaluation needs
to be rethought and indicators should be developed that provide
for an evidence based evaluation. Further, we believe that, in
general, more transparency is needed regarding public funding of
research and its socially meaningful outcomes. Therefore, in
Germany and elsewhere, by law public research funding should be
linked to its measurable outputs, not only in the form of patents,
but also in terms of commercialisation of these patents.
At a more complex level is a consideration of what the value and
consequences of a patented invention implies. So et al emphasise
that the benefits of patenting and licensing must always be
weighted against the social cost of a licenses’ exclusivity [14]. The
commercial and the societal value of a particular invention may be
very different. Medical research on tropical diseases is often
neglected because its profitable commercial value is low - and yet
its social value may be very high, potentially saving millions of lives
or life-years. The commercial and societal value of different
inventions and patents can vary depending on what ‘society’ is
considered. The value of a patent for a drug needed by the poor in
a low-income country will be different than when considering its
worldwide implications or applications. Finally, the social value is
very difficult and controversial to define.
We found that the majority of the increase in patent
applications has been for submissions either to WIPO or only to
the German Patent and Trademark Office. A WIPO application
might be only used in certain countries, for example only high-
income countries such as the US and European states. But it can
also lead to patents in almost all states of the world, including low-
income countries. It could be the case that those applying are
aiming for high-income countries with clear intentions for
commercialisation. This would be in line with the theoretical
underpinning and justifications of the legal reforms. We believe
there is a need for more discussion, in Germany and internation-
ally, on what responsibility PROs and national governments have
to prevent or manage the negative consequences of increased
patenting and licensing. What policies are or should be in place to
clarify the responsibilities these institutions have to protect? Are
these policies prioritising the public good and holding the
institutions accountable to it? We believe in particular that policies
on the use of publicly funded research must be transparent to the
public.
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research output and effectiveness of universities. The traditional
ranking in science is the number of publications, and indeed
evidence suggests that number of publications and patenting levels
are often associated [16,52,53]. However, the increase in patent
applications may be a reflection of the effectiveness of the TTOs
and administrative structures, rather than increased inventiveness
or productivity of researchers at universities or non-university
PROs. This seems to suggest that ranking patent submissions is a
questionable indicator of the success, efficiency and productivity of
a PRO. The use of patents as a ranking for inventiveness of PROs
must therefore be reconsidered, or at least appropriately
developed, in relation to publishing indexes and other established
or verifiable indicators.
Limitations
The complexity and number of issues we encountered in
developing this method highlights how complex the use of a patent
database system is. Though publicly available, mining empiric
information from such a database is not a simple task; in fact it
appears that the databases are designed for searching information
on single patents. We are aware that the limited sensitivity of our
method is not suitable for exhaustive evaluation of the patent
landscape on a specific topic. Nonetheless, we have developed a
multi-step method that allows IP laypersons – like researchers in
the sector of medicine – to familiarize themselves with patents in
their field of research.
It was not within the scope of the current analysis to weight or
contextualise individual PROs, for example by PRO size or
volume of research funding received, or even distinguish the
applicability of such factors in contributing to meaningful
interpretation of our results. Our data gives no information on
licensing of patents – this is typically provided by commercial data
providers.
Nevertheless, analysing patent applications is a first step to lay
the foundation for further evaluation of the commercialisation of
patents, the main argument for IP protection of publicly funded
research.
Conclusions
In 2002, IP legal reforms designed to encourage commercialisa-
tion of publicly funded research were introduced in Germany.
We have developed and present a new method to extract and
process data on patent applications for medical science inventions
by universities and non-university public research organisations in
Germany using a publicly accessible database.
Overall, we identified 1772 health related patent families
applied for by 193 different universities and non-university PROs
since 1988. 872 (47%) of these families included granted patents.
Patenting by universities and university-affiliated institutions
account for the majority of submitted patent applications. Since
the introduction of IP reforms patent applications by universities
have tripled and relatively increased for PCT countries, whereas
non-university PROs patent applications have remained stable.
However, there can be various reasons other than instigated policy
changes for this increase in PROs’ patent applications.
Empirical evidence analysing Bayh-Dole-type policy changes in
developed countries, particularly the US, do not conclusively
demonstrate the commercial viability of increased patenting of
publicly funded inventions. Publicly available data on patenting
from publicly funded research institutions in Germany does not
allow conclusions to be drawn regarding commercial viability of
patents.
Licensing agreements that commercially exploit patented
inventions from publicly funded research need to be made
publicly accessible, to allow for empirical, evidence based policy
analysis.
In the future, publicly funded research results should not only be
measured by their patenting and commercial successes, but also in
terms of their social and global health relevance.
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